Eladur, an investigational transdermal drug patch for low back pain, did not meet goals in a double-blind study, according to a report by its maker, Durect.
Eladur delivers for up to three days bupivacaine, an FDA-approved long-acting local anesthetic used in regional anesthesia for local tissue infiltration, nerve block, and epidural and intrathecal anesthesia.
“Demonstrating efficacy against placebo in a chronic low back pain trial is challenging for any topical locally acting product,” said James E. Brown, president and CEO of Durect. “We and Pfizer are continuing to analyze this most recent study and will work together to determine next steps.”
Read the Durect report on Eladur.
Read more coverage of low back pain.
– Imaging Doesn’t Benefit Most Low Back Pain
– Study Finds Many Back Pain Patients Overtreated
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
